At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
vitamin D3drug
Likely dose
vitamin D3 10,000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
In Brief
A clinical study evaluating vitamin D3 for Breast Cancer. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The overall goal of this project is to determine if high dose vitamin D3 given to premenopausal women at high risk for development of breast cancer, who initially have insufficient levels of 25-hydroxy vitamin D (\<30 ng/ml), will raise 25(OH)D levels above 50 ng/ml. If so, will certain risk biomarkers for development of breast cancer be reliably and favorably modulated?
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsBTR Group
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
First PostedJul 2010
Primary CompletionJun 2011
TodayJul 2026
First PostedJul 21, 2010
Enrollment StartMay 1, 2009
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.9 years ago
Interventions
vitamin D3drug
oral capsules, 10,000 IU per week for 6 months